What are BioCryst Pharmaceuticals's total assets?

BioCryst Pharmaceuticals (BCRX) holds $465.1M in total assets, down 3.1% year over year.

How much debt does BioCryst Pharmaceuticals have?

BioCryst Pharmaceuticals carries $411.8M in total debt against -$553.8M of shareholders' equity, a debt-to-equity ratio of 0.14.

How much cash does BioCryst Pharmaceuticals have?

BioCryst Pharmaceuticals holds $173.4M in cash and equivalents.

Can BioCryst Pharmaceuticals cover its short-term obligations?

Its current ratio is 1.91 — current assets exceed current liabilities.

Where does BioCryst Pharmaceuticals's balance sheet data come from?

Every line is extracted from BioCryst Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

BioCryst Pharmaceuticals BCRX Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Cash and cash equivalents	$91.34M-14.1%	$106.32M-5.4%	$112.45M-63.1%	$304.77M-39.6%
Short-term investments	$185.01M-14.4%	$216.14M-22.3%	$278.34M+133%	$119.54M+3,622%
Restricted cash	$201K-4.3%	$210K-88.4%	$1.8M+22.6%	$1.47M-56.0%
Accounts receivable, net	$106.82M+35.1%	$79.07M+3,344%	$2.3M-72.2%	$8.27M-71.9%
Inventories	$23.99M+3.5%	$23.19M—	$0-100%	$28.71M+81.8%
Raw materials	$10M-0.1%	$10.01M+55.2%	$6.45M-27.6%	$8.91M—
Work in process	$12.89M-20.2%	$16.15M-8.2%	$17.59M+17.4%	$14.99M—
Finished goods	$7.28M-6.3%	$7.77M+24.4%	$6.24M+29.7%	$4.81M—
Prepaid expenses and other current assets	$17.18M+24.9%	$13.75M-29.6%	$19.54M+55.3%	$12.59M+26.0%
Trading assets	$185.01M-14.4%	$216.14M-22.3%	$278.34M+133%	$119.54M—
Derivative assets	$13.74M—	——	——	——
Total current assets	$404.35M-4.2%	$421.97M-14.9%	$495.97M-4.0%	$516.5M-8.8%
Property and equipment, net	$8.78M+12.9%	$7.78M-1.7%	$7.91M-8.2%	$8.62M-1.1%
Operating lease right-of-use assets	10.7%-0.2%	10.9%0.0%	10.9%-0.1%	11%—
Other non-current assets	$5.67M+10.0%	$5.16M+6,346%	$80K-98.8%	$6.81M+5.2%
Equity method investments	$61.16M+201%	$20.32M—	$0-100%	$18.08M+165%
Total assets	$514.16M+4.8%	$490.42M-5.1%	$516.96M-6.0%	$550M-6.5%
Accounts payable	$15.83M+35.9%	$11.64M-44.3%	$20.89M+45.5%	$14.36M-48.4%
Accrued expenses	$126.41M+11.6%	$113.29M+10.1%	$102.88M+17.5%	$87.57M+20.5%
Deferred revenue	$0—	——	$0-100%	$1.22M-13.9%
Current portion of long-term debt	$1.31M-28.5%	$1.84M+15.4%	$1.59M+86.4%	$853K—
Operating lease liabilities, current	$317K-66.2%	$937K-11.4%	$1.06M-30.2%	$1.52M-16.7%
Finance Lease Liability, Current	$1.31M-28.5%	$1.84M+15.4%	$1.59M+86.4%	$853K—
Contract liabilities	$0—	——	——	——
Accrued interest	$1.49M+33.0%	$1.12M+730%	$135K-72.3%	$487K—
Total current liabilities	$196.07M+22.2%	$160.38M+6.9%	$149.99M+42.1%	$105.51M+1.7%
Long-term debt	$0-100%	$314.87M+3.8%	$303.23M+30.9%	$231.62M+70.2%
Operating lease liabilities, non-current	$8.57M+8.2%	$7.92M-5.6%	$8.39M+108%	$4.03M-32.5%
Finance Lease Liabilities (Total)	$2.75M-30.5%	$3.96M-10.7%	$4.44M+68.6%	$2.63M—
Operating Lease Liabilities (Total)	$8.89M+0.3%	$8.86M-6.2%	$9.45M+70.4%	$5.54M-28.8%
Finance lease liabilities	$1.44M-32.2%	$2.12M-25.3%	$2.85M+60.1%	$1.78M—
Total liabilities	$633.31M-34.5%	$966.35M-0.6%	$972.49M—	——
Preferred stock	$0—	$0—	$0—	$0—
Common stock	450M+21,483%	2.1M+1.3%	2.1M+9.5%	1.9M+2.0%
Additional paid-in capital	$1.38B+7.3%	$1.29B+5.6%	$1.22B+5.5%	$1.16B+5.4%
Retained earnings	-$1.51B+14.9%	-$1.77B-5.3%	-$1.68B-15.6%	-$1.45B-20.5%
Accumulated other comprehensive income (loss)	$38K-95.9%	$921K-31.1%	$1.34M+5,042%	$26K-85.3%
Total stockholders' equity	-$119.15M+75.0%	-$475.93M-4.5%	-$455.53M-54.6%	-$294.6M-175%
Total liabilities and stockholders' equity	$514.16M+4.8%	$490.42M-5.1%	$516.96M-6.0%	$550M-6.5%
Available-for-Sale Debt Securities - Amortized Cost	$244.46M+4.1%	$234.9M-15.5%	$278.13M+101%	$138.2M—
AFS and Trading Securities - Unrealized Loss Position Fair Value	——	——	——	——
Cash, Cash Equivalents, and Marketable Securities	——	——	$278.34M—	——
Other Inventory, Net	$775K-70.7%	$2.65M+65.7%	$1.6M+35.9%	$1.18M—
Deferred Tax Assets and Other Non-Current Assets	$5.67M+10.0%	$5.16M+6,346%	$80K-98.8%	$6.81M+5.2%
Investments	$61.16M+201%	$20.32M—	$0-100%	$18.08M+165%
Other non-current assets	$5.67M+10.0%	$5.16M+6,346%	$80K-98.8%	$6.81M+5.2%
Right of use assets, net	$10.2M-15.0%	$12.01M-7.7%	$13M—	——
Short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84)	$185.01M-14.4%	$216.14M—	——	——
Software and Technology Licenses, Net	$5.67M+10.0%	$5.16M+6,346%	$80K-98.8%	$6.81M+5.2%
Accrued Progress Collections and Price Adjustments	$0—	——	——	——
Other Commercial Liabilities	$126.41M+11.6%	$113.29M+10.1%	$102.88M+17.5%	$87.57M+20.5%
Accrued Liabilities, Current	$126.41M+11.6%	$113.29M+10.1%	$102.88M+17.5%	$87.57M+20.5%
Royalty financing obligations	$38.46M+17.7%	$32.68M+38.7%	$23.57M—	——
Share-based liability	$13.74M—	$0—	——	——
Finance Lease Liability Payment Due	——	——	——	——
Finance Lease Liability - Undiscounted Excess Amount	——	——	——	——
Lease Liability Payments - 2020 (Remaining Three Months)	——	——	——	——
Lease Liability Payments - 2021	——	——	——	——
Operating Lease Liability Payments - 2024 (Lessee)	——	——	——	——
Operating Lease Liability Payments - 2025 (Lessee)	——	——	——	——
Lease Liability Payments - Due Year Two	——	——	——	——
Lease Liability Payments - Due Year Three	——	——	——	——
Lease Liability Payments - Due Year Four	——	——	——	——
Lease Liability Payments - Remainder of Fiscal Year	——	——	——	——
Operating Lease Liability Payments Due	——	——	——	——
Operating Lease Liability - Undiscounted Excess Amount	——	——	——	——
Restructuring Reserve	$5.48M—	——	$3.38M—	——
Contract Liabilities, Non-Current	$0—	——	——	——
Operating Lease Liability Payments - 2026 (Lessee)	——	——	——	——
Operating Lease Liability Payments - 2027 (Lessee)	——	——	——	——
Operating Lease Liability Payments - 2028 (Lessee)	——	——	——	——
Deferred revenue, net of current portion	$0—	——	——	——
Total debt	$12.95M-96.1%	$329.52M+3.4%	$318.7M+32.4%	$240.65M+67.3%
Common Stock Shares Issued	213.1M+2.2%	208.5M+1.3%	205.8M+9.5%	187.9M—
Convertible Preferred Stock Authorized Shares	5M0.0%	5M0.0%	5M0.0%	5M—
Convertible Preferred Stock Issued Shares	0—	0—	0—	0—
Convertible Preferred Stock Outstanding Shares	0—	0—	0—	0—
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$2.13M+2.2%	$2.09M+1.3%	$2.06M+9.5%	$1.88M+2.0%
Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding	$0—	$0—	$0—	$0—
Investments - Gross Unrealized Losses	——	——	——	——
Preferred Stock Par Value Per Share	$0.010.0%	$0.010.0%	$0.010.0%	$0.01—
Shares Reserved for Future Issuance Under Stock Plans	68.5M+10.2%	62.2M+7.1%	58M-13.7%	67.2M—
Unrealized Gains on Investments	$234K-48.1%	$451K+201%	$150K—	$0—
Unrealized Losses on Investments (Before Tax)	$5K-64.3%	$14K-80.6%	$72K-93.2%	$1.06M—
Components	——	——	——	——
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax	$5K-64.3%	$14K-80.6%	$72K-93.2%	$1.06M—
Gross Unrealized Gains	$234K-48.1%	$451K+201%	$150K—	$0—
Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One	$185.01M-14.4%	$216.14M-22.3%	$278.34M+133%	$119.54M—
Available for sale investments	$246.18M+4.1%	$236.46M-15.0%	$278.34M+102%	$137.62M—
Cash, cash equivalents, and investments	$335.91M-1.5%	$341.17M—	——	——
Common stock, capital shares reserved for future issuance	$68.5M+10.2%	$62.16M+7.1%	$58.02M-13.7%	$67.24M—
Common stock, shares authorized (in shares)	$450M0.0%	$450M0.0%	$450M0.0%	$450M—
Common stock, shares issued (in shares)	$213.06M+2.2%	$208.54M+1.3%	$205.77M+9.5%	$187.91M—
Common Stock, Shares, Outstanding	$213.06M+2.2%	$208.54M+1.3%	$205.77M+9.5%	$187.91M—
Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss	$244.46M+4.1%	$234.9M-15.5%	$278.13M+101%	$138.2M—
Maturing after one year through two years	$61.16M+201%	$20.32M—	——	——
Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions	——	——	——	——
Debt Securities, Available-for-Sale, Unrealized Loss Position	——	——	——	——
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis with Unobservable Inputs	$13.74M—	——	——	——
Current maturities of long-term debt	$1.31M-28.5%	$1.84M+15.4%	$1.59M+86.4%	$853K—
Finance Lease Liability Payments Due	——	——	——	——
2027	——	——	——	——
Finance Lease Liability Payments Due Year Four	——	——	——	——
Finance Lease Liability Payments Due Year Three	——	——	——	——
Finance Lease Liability Payments Due Year Two	——	——	——	——
Thereafter	——	——	——	——
Finance Lease Liability Undiscounted Excess Amount	——	——	——	——
Inventory, Including Noncurrent Portion	$29.39M-6.0%	$31.27M+9.0%	$28.68M—	——
Raw materials	$10M-0.1%	$10.01M+55.2%	$6.45M-27.6%	$8.91M—
Lessee Operating Lease Liability Payments Due	——	——	——	——
Thereafter	——	——	——	——
Lessee Operating Lease Liability Undiscounted Excess Amount	——	——	——	——
Operating Lease Weighted Average Discount Rate Percent	$0.11-1.9%	$0.11+0.3%	$0.11-1.1%	$0.11—
Preferred Stock, Par or Stated Value Per Share	$0.010.0%	$0.010.0%	$0.010.0%	$0.01—
Preferred Stock, Shares Authorized	$5M0.0%	$5M0.0%	$5M0.0%	$5M—
Preferred Stock, Shares Issued	$0—	$0—	$0—	$0—
Preferred Stock, Shares Outstanding	$0—	$0—	$0—	$0—
Restricted cash in other assets	——	——	——	——
Restructuring Reserve	$5.48M—	——	$3.38M—	——
Royalty Financing Liabilities	$465.69M-9.4%	$513.73M-3.4%	$531.6M—	——
Royalty financing obligations	$427.23M-11.2%	$481.05M-5.3%	$508.03M—	——
Number of plans	——	——	——	——
Remainder of Fiscal Year 2024	——	——	——	——
Weighted-Average Discount Rate	9.8%+1.1%	8.7%+1.2%	7.5%—	——
Weighted-Average Discount Rate - Finance Leases	$0.1+12.8%	$0.09+16.1%	$0.07—	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about BioCryst Pharmaceuticals.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are BioCryst Pharmaceuticals's total assets?: BioCryst Pharmaceuticals (BCRX) holds $465.1M in total assets, down 3.1% year over year.
How much debt does BioCryst Pharmaceuticals have?: BioCryst Pharmaceuticals carries $411.8M in total debt against -$553.8M of shareholders' equity, a debt-to-equity ratio of 0.14.
How much cash does BioCryst Pharmaceuticals have?: BioCryst Pharmaceuticals holds $173.4M in cash and equivalents.
Can BioCryst Pharmaceuticals cover its short-term obligations?: Its current ratio is 1.91 — current assets exceed current liabilities.
Where does BioCryst Pharmaceuticals's balance sheet data come from?: Every line is extracted from BioCryst Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.